Human Reproductive Technologies

Human Reproductive Technologies

Global Human Reproductive Technologies Market to Reach US$34.6 Billion by 2030

The global market for Human Reproductive Technologies estimated at US$29.6 Billion in the year 2023, is expected to reach US$34.6 Billion by 2030, growing at a CAGR of 2.3% over the analysis period 2023-2030. Contraceptive Drugs & Devices, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$22.0 Billion by the end of the analysis period. Growth in the Infertility Treatment segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.0 Billion While China is Forecast to Grow at 3.9% CAGR

The Human Reproductive Technologies market in the U.S. is estimated at US$8.0 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 3.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Human Reproductive Technologies Market - Key Trends and Drivers Summarized

The human reproductive technologies market is experiencing substantial growth due to a confluence of demographic shifts, technological advancements, and evolving societal norms. This sector includes a variety of treatments and technologies designed to address fertility and reproduction challenges, with increasing demand driven by higher infertility rates and shifting trends towards later family planning. Factors such as lifestyle changes, delayed childbearing, and higher consumption of substances affecting fertility contribute to the growing prevalence of infertility, prompting greater reliance on reproductive technologies. Medical advancements are making these technologies more accessible and effective, enhancing their adoption across the globe. In particular, the contraceptive segment holds a significant market share due to the ease of use, widespread availability, and simple administration of oral contraceptives, further supported by government initiatives aimed at preventing unplanned pregnancies and promoting sexual health.

In terms of technological innovation within this sector, assistive reproductive technologies (ART) like in vitro fertilization (IVF) have seen notable developments. The integration of intellectual property (IP) into ART, especially with emerging technologies such as in vitro gametogenesis (IVG), is reshaping the landscape. IVG, which involves reprogramming cells to develop into sperm or eggs, represents a significant shift from traditional methods by potentially allowing genetic selection and modification previously unattainable. The approach to IP in this realm has evolved from a collaborative, open-sharing model to a more competitive one, with researchers and companies increasingly seeking to secure patents. This shift is influenced by the substantial financial potential of IVG, although it also brings complex ethical and regulatory challenges that could affect the scope and viability of patentable material in reproductive technologies.

The expansion of the human reproductive technologies market is propelled by several key drivers. Innovations such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD) continue to revolutionize fertility treatments, enhancing their effectiveness and broadening their appeal. The growing societal acceptance of ART has reduced stigma and increased usage, particularly among diverse family structures, including single parents by choice and LGBTQ+ families. Additionally, the expansion of healthcare financing options, increased commercial investments, and supportive legislative changes have made these technologies more accessible and popular. Moreover, advancements in genetic screening and the trend toward personalized medicine are enabling more tailored and effective fertility treatments. Collectively, these factors are fostering a dynamic market environment where reproductive technologies are not only advancing in capability but also becoming more integrated into societal frameworks and expectations, significantly impacting how future generations are conceived and born.

 

Select Competitors (Total 12 Featured) -

• Ansell Healthcare LLC
• Ansell Ltd.
• Apothecus Pharmaceutical Corporation
• Bayer AG
• Cipla Ltd.
• Ferring Pharmaceuticals, Inc.
• Indian Drugs & Pharmaceuticals Ltd.
• Janssen Pharmaceuticals, Inc.
• Johnson & Johnson
• Lupin Ltd.
• Mankind Pharma Ltd.
• Mapa GmbH
• Merck & Co., Inc.
• Merck KGaA
• Pfizer, Inc.
• The Female Health Company (FC2)
• T-MARC Tanzania

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.